STOCK TITAN
  1. Home
  2. News
  3. CLLS

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Positive
  • None.
Negative
  • None.

PARIS, March 04, 2024 (GLOBE NEWSWIRE) --

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital		Total number of voting rights
02/29/202471,751,20177,686,895

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com  

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment


Cellectis had a total of 77,686,895 voting rights in February 2024.

Cellectis had 71,751,201 shares in the capital in February 2024.

Cellectis is listed on Euronext Growth.

Cellectis' ISIN code is FR0010425595.

For media inquiries at Cellectis, contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or Patricia Sosa Navarro at +33 (0)7 76 77 46 93.

The Investor Relations contacts for Cellectis are Arthur Stril at +1 (347) 809 5980 and Ashley R. Robinson at +1 617 430 7577.
Stock CLLS logo
Cellectis

NASDAQ:CLLS

CLLS Rankings

#3865 Ranked by Market Cap
#4900 Ranked by Stock Gains
N/A Ranked by Dividends

CLLS Latest News

Apr 22, 2024
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Apr 10, 2024
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Apr 8, 2024
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Apr 4, 2024
Monthly information on share capital and company voting rights
Feb 2, 2024
Monthly information on share capital and company voting rights

CLLS Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.